================================================================================


                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                       -----------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

         Date of Report (Date of earliest event reported): April 3, 2000



                         ------------------------------
                         COMMISSION FILE NUMBER 0-17714
                         ------------------------------



                           Biopool International, Inc.
             (Exact name of Registrant as specified in its charter)




           DELAWARE                                       58-1729436
(State or other jurisdiction of                      (I.R.S. Employer
 incorporation or organization)                       Identification No.)



                               6025 NICOLLE STREET
                            VENTURA, CALIFORNIA 93003
                    (Address of principal executive offices)



                                 (805) 654-0643
               (Registrant's telephone number including area code)




================================================================================








ITEM 5.        OTHER EVENTS

     Reference is made to the press  release of  Registrant,  issued on April 3,
2000,  which contains  information  meeting the requirements of this Item 5, and
which is incorporated  herein by this reference.  A copy of the press release is
attached to this Form 8-K as Exhibit "A."










                                   SIGNATURES


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.





Date:       APRIL 5, 2000                      BIOPOOL INTERNATIONAL, INC.
       --------------------------              ---------------------------
                                               (Registrant)





                                               /S/ MICHAEL D. BICK, PH.D.
                                               --------------------------
                                               Michael D. Bick, Ph.D.
                                               Chief Executive Officer and
                                               Chairman of the Board


                                        2



                                    EXHIBIT A



CONTACTS:              Michael D. Bick, Ph.D.
                       Chairman and Chief Executive Officer

                       Carol Hill
                       Corporate Communications
                       (805) 654-0643


FOR IMMEDIATE RELEASE

                  COMPLAINT ALLEGING PATENT INFRINGEMENT FILED
                          AGAINST BIOPOOL INTERNATIONAL

VENTURA, California (April 3, 2000) -- Biopool International, Inc. (OTC BB:BIPL)
today  reported  that Agen  Biomedical  Limited,  a  wholly-owned  subsidiary of
Biotech  International  Limited  (BII.AX),  an Australian  corporation,  filed a
complaint  against  the  Company  in  U.S.  District  Court  in  San  Francisco,
California, March 10, 2000. The complaint alleges that Biopool's manufacture and
sale of D-dimer  test kits in the U.S.  directly  infringes  Agen's U.S.  patent
4,758,524.
           Michael D.  Bick,  Ph.D.,  chairman  and chief  executive  officer of
Biopool,  commented,  "We have  prepared  and filed an answer.  We  believe  the
complaint  to be without  merit and that it will have no material  impact on our
financial position or results of operations."
           Founded in 1987, Biopool International  develops,  manufactures,  and
markets a full  range of test kits to assess  and  diagnose  disorders  of blood
coagulation,  thrombotic risk factors, fibrinolysis,  platelet function, and the
vascular  system and specialty  toxicology  controls used to monitor and measure
the presence of drugs of abuse. The Company's product line is sold to hospitals,
clinical   laboratories,   commercial  reference   laboratories,   and  research
institutions on a worldwide basis by the Company's own sales representatives, as
well as  through  an  extensive  network  of  distributors.  To learn more about
Biopool, visit the Company's website at http://www.biopool.com.

NOTE:  This press  release  contains  forward-looking  statements  including the
expectation  that a complaint  filed  against the Company  will have no material
impact on the Company's  financial position or results of operations,  which are
based upon current expectations that involve a number of risks and uncertainties
including, but not limited to, technological innovations of competitors, changes
in health care regulations,  litigation  claims,  foreign currency  fluctuation,
product  acceptance  or  changes  in  government  regulation  of  the  Company's
products,  as well as other factors  discussed in the  Company's  last Report on
Form 10-K-SB under "Risk Factors."

                                      # # #

                                        3